Canbex Therapeutics Overview
- Status
-
Acquired/Merged
- Employees
-
4
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$109M
- Investors
-
1
Canbex Therapeutics General Information
Description
Operator of a drug development company based in London, United Kingdom The company provides cannabinoid agonists for the treatment of spasticity in multiple sclerosis and other related disorders.
Contact Information
Website
www.canbex.co.ukCorporate Office
- London BioScience Innovation Centre
- 2 Royal College Street
- London NW1 0NH
- England, United Kingdom
Corporate Office
- London BioScience Innovation Centre
- 2 Royal College Street
- London NW1 0NH
- England, United Kingdom
Canbex Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Merger/Acquisition | 24-Feb-2015 | $109M | Completed | Generating Revenue | ||
| 4. Grant | 06-Sep-2013 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series A) | 11-Apr-2013 | Completed | Generating Revenue | |||
| 2. Early Stage VC | Completed | Startup | ||||
| 1. University Spin-Out | 01-Mar-2004 | Completed | Startup |
Canbex Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Ordinary 2 | ||||||||
| Ordinary 1 | 172,580 | $4.43 | $4.43 | 1x | $4.43 | 22.23% |
Canbex Therapeutics Patents
Canbex Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-201516494-D0 | New therapeutic use | Inactive | 17-Sep-2015 | ||
| EP-3256122-A1 | Bkca channel activator for treating muscular disorder | Inactive | 13-Feb-2015 | ||
| US-20180021303-A1 | Bkca channel activator for treating muscular disorder | Inactive | 13-Feb-2015 | ||
| WO-2016128772-A1 | Bkca channel activator for treating muscular disorder | Inactive | 13-Feb-2015 | ||
| EP-3256112-A1 | Compounds for treating disorders associated with bk channel modulation | Inactive | 13-Feb-2015 | A61K31/166 |
Canbex Therapeutics Signals
Canbex Therapeutics Former Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Bloomsbury Bioseed Fund | Venture Capital | Minority | ||
| Esperante Ventures | Corporate Venture Capital | Minority | ||
| M Ventures | Corporate Venture Capital | Minority | ||
| UCL Ventures | University | Minority | ||
| Wellcome Trust | Limited Partner | Minority |
Canbex Therapeutics FAQs
-
Where is Canbex Therapeutics headquartered?
Canbex Therapeutics is headquartered in London, United Kingdom.
-
What is the size of Canbex Therapeutics?
Canbex Therapeutics has 4 total employees.
-
What industry is Canbex Therapeutics in?
Canbex Therapeutics’s primary industry is Drug Discovery.
-
Is Canbex Therapeutics a private or public company?
Canbex Therapeutics is a Private company.
-
What is the current valuation of Canbex Therapeutics?
The current valuation of Canbex Therapeutics is .
-
What is Canbex Therapeutics’s current revenue?
The current revenue for Canbex Therapeutics is .
-
How much funding has Canbex Therapeutics raised over time?
Canbex Therapeutics has raised $4.99M.
-
Who are Canbex Therapeutics’s investors?
Bloomsbury Bioseed Fund, Esperante Ventures, M Ventures, UCL Ventures, and Wellcome Trust have invested in Canbex Therapeutics.
-
When was Canbex Therapeutics acquired?
Canbex Therapeutics was acquired on 24-Feb-2015.
-
Who acquired Canbex Therapeutics?
Canbex Therapeutics was acquired by Ipsen.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process